Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.36 |
| ▸ | CA1 | P00915 | 4/20 | 0.36 |
| ▸ | CA9 | Q16790 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13985292 | 0.82 | CA2 (0.39) | CA2CA1CA9TSHRMMP1 | |
| SCHEMBL13985297 | 0.74 | CA2 (0.39) | CA2CA1CA9TSHRMMP1 | |
| SCHEMBL7155167 | 0.74 | LMNA (0.35) | CA2CA1CA9TSHRMMP1 | |
| SCHEMBL10478941 | 0.72 | CA2 (0.64) | CA2CA1CA9CA12 | |
| SCHEMBL13365650 | 0.72 | CA1 (0.37) | CA2CA1CA9 | |
| SCHEMBL7566969 | 0.71 | KMT2A (0.37) | CA2CA1CA9 | |
| SCHEMBL2456071 | 0.71 | CA2 (0.36) | CA2CA1CA9TSHRMMP1 | |
| SCHEMBL2503399 | 0.69 | KMT2A (0.47) | CA2CA1CA9 | |
| SCHEMBL16367194 | 0.69 | KMT2A (0.47) | CA2CA1CA9 | |
| SCHEMBL12391259 | 0.69 | KMT2A (0.47) | CA2CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376428-A2 | NEW INHIBITORS FOR TREATING DISEASES ASSOCIATED WITH AN EXCESS TRANSPORT OF HYALURONAN | Universitätsklinikum Münster (DE) | 2011-10-19 | — | — | EP | disclosed |
| US-20110245335-A1 | NEW INHIBITORS FOR TREATING DISEASES ASSOCIATED WITH AN EXCESS TRANSPORT OF HYALURONAN | UNIVERSITAETSKLINIKUM MUENSTER (DE) | 2011-10-06 | — | — | US | disclosed |
| WO-2010066909-A2 | NEW INHIBITORS FOR TREATING DISEASES ASSOCIATED WITH AN EXCESS TRANSPORT OF HYALURONAN | Universitätsklinikum Münster (DE) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245335-A1 | NEW INHIBITORS FOR TREATING DISEASES ASSOCIATED WITH AN EXCESS TRANSPORT OF HYALURONAN | SLC10A1, ABCB11, HEXD | CA2 854/4885CA1 2183/4885CA9 656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.